ANNX · XBRL financial data

Annexon financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ANNX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	49,271	100,066	112,501	113,756	119,448	184,698
General and administrative	14,198	30,647	33,098	29,967	34,625	31,709
Total operating expenses	63,469	130,713	145,599	143,723	154,073	216,407
Operating income (loss)	(63,469)	(130,713)	(145,599)	(143,723)	(154,073)	(216,407)
Other income (expense)	57	—	—	—	—	—
Income tax expense (benefit)	—	—	0	0	0	0
Net income (loss)	(63,412)	(130,323)	(141,947)	(134,237)	(138,200)	(206,690)
Earnings per share, basic USD per share	—	(3.40)	(2.60)	(1.77)	(1.01)	(1.34)
Earnings per share, diluted USD per share	—	(3.40)	(2.60)	(1.77)	(1.01)	(1.34)
Weighted average shares, basic thousands of shares	—	38,316	54,674	75,673	137,404	155,106
Weighted average shares, diluted thousands of shares	—	38,316	54,674	75,673	137,404	155,106

Fiscal years (ANNX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	268,565	74,843	140,020	225,110	49,498	162,051
Marketable securities	82,641	167,872	102,637	34,606	262,519	76,294
Prepaid and other current assets	2,805	4,978	5,441	4,144	4,444	3,846
Total current assets	354,011	247,693	248,098	263,860	316,461	242,191
Property and equipment, net	1,935	17,848	16,838	14,773	12,638	10,617
Right-of-use asset	—	20,333	19,128	18,009	16,705	15,185
Total assets	355,946	287,040	285,096	297,674	350,071	277,571
Accounts payable	3,734	11,153	7,416	5,487	10,426	14,931
Accrued liabilities	6,497	9,250	13,448	10,235	—	—
Total current liabilities	10,622	21,744	22,360	17,928	30,512	42,630
Lease liability, non-current	—	33,387	31,542	29,190	26,454	23,293
Total liabilities	11,668	55,131	53,902	47,118	56,966	65,923
Accumulated deficit	(165,992)	(296,315)	(438,262)	(572,499)	(710,699)	(917,389)
Total stockholders' equity	344,278	231,909	231,194	250,556	293,105	211,648
Total liabilities and equity	355,946	287,040	285,096	297,674	350,071	277,571
Common shares outstanding (cover page) thousands of shares	38,158	38,564	47,723	78,369	109,382	149,363

Fiscal years (ANNX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(63,412)	(130,323)	(141,947)	(134,237)	(138,200)	(206,690)
Stock-based compensation	4,888	16,262	18,516	18,183	19,433	16,423
Depreciation and amortization	667	2,141	2,106	2,148	2,150	2,166
Net cash from operating activities	(53,087)	(106,110)	(116,309)	(121,142)	(118,006)	(186,356)
Purchases of property and equipment	464	1,654	6,526	193	15	137
Net cash from investing activities	(83,164)	(88,236)	58,443	70,703	(218,797)	190,052
Proceeds from issuing common stock	—	—	—	17,995	44,371	28,488
Net cash from financing activities	360,876	1,795	122,908	135,524	161,206	108,855

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Annexon	199,270	not reported	(48,007)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	165,700	1,600	(51,500)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Corvus Pharmaceuticals	18,905	not reported	(15,398)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026
Verastem	136,353	40,078	(43,909)*	90.6M	3.1 quarters	Q2 FY26 10-QJun 30, 2026
Heron Therapeutics	20,721	not reported	(2,213)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Aldeyra Therapeutics	45,090	not reported	(4,589)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Sagimet Biosciences	165,896	not reported	(11,099)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
Atea Pharmaceuticals	76,548	not reported	(37,084)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Lifecore Biomedical	23,035	25,322	6,946*	37.9M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.